<DOC>
	<DOCNO>NCT01782651</DOCNO>
	<brief_summary>This study describe treatment paradigm use recent year clinical management Human Epidermal Growth Factor Receptor 2 ( HER2 ) + metastatic breast cancer Hungary . This information provide insight real-world exposure adherence anti-HER2 therapy contain regimen , improve understand reason discontinuation therapy . This retrospective , descriptive , cohort study approximately 180 female patient diagnose HER2-positive metastatic breast cancer Hungary . Patients diagnose , progress , metastatic disease 01 September 2009 01 September 2010 include . All patient follow death , loss follow-up end study period ( 30 September 2012 ) . All data collect retrospectively patient medical record . Descriptive statistic demographic clinical characteristic HER2+ metastatic breast cancer patient , include site metastasis , time initial breast cancer diagnosis diagnosis metastatic disease , HER2 test methodology status HER2 describe . Further , descriptive statistic proportion HER2+ metastatic breast cancer patient receive anti-HER2 therapy , sequence different therapy , duration therapy metastatic setting analyse . Among subset woman receive lapatinib plus capecitabine , descriptive statistic time initiation lapatinib plus capecitabine metastatic treatment pathway , time treatment discontinuation time progression ( TTP ) lapatinib plus capecitabine calculate . Further , descriptive statistic type duration anti-HER2 therapy use prior initiation lapatinib plus capecitabine , relevant , lapatinib+capecitabine perform .</brief_summary>
	<brief_title>Treatment Options Human Epidermal Growth Factor Receptor 2 ( HER2 ) Positive Metastatic Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Female patient age 18 year old diagnosis , progression , metastatic breast cancer Patients diagnosis breast cancer document metastatic disease know date metastatic disease Patients histologically confirm HER2+ breast cancer ( HER2 test procedure per routine institutional practice ; tissue resampling perform . If conduct another site , documented result must available ) . Patients receive care another primary cancer study time period .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>HER2 positive</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>treatment pattern</keyword>
</DOC>